Skip to main content
Clinical Trials/NCT02784899
NCT02784899
Completed
Not Applicable

Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation

Yonsei University1 site in 1 country40 target enrollmentOctober 8, 2015

Overview

Phase
Not Applicable
Intervention
iloprost
Conditions
Lung Cancer
Sponsor
Yonsei University
Enrollment
40
Locations
1
Primary Endpoint
PaO2(partial pressure of arterial oxygen) ratio
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

One lung ventilation (OLV) is essential during thoracic surgery. During OLV, intrapulmonary shunt can be increased resulting hypoxemia. Although OLV technique had been advanced so far, hypoxemia during OLV reaches about 10% in spite of inspired oxygen fraction 100%. Iloprost is a prostaglandin analogue used for pulmonary hypertension, which can decrease pulmonary artery resistance by selectively dilating pulmonary artery. In this prospective, randomized, double blind study, investigators are planning to investigate the effects of iloprost on respiratory physiology (intrapulmonary shunt, deadspace, oxygenation, etc).

Registry
clinicaltrials.gov
Start Date
October 8, 2015
End Date
June 30, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • scheduled for Video-assisted thoracoscopic surgery (VATS) lobectomy
  • 40 \< age \< 80
  • American Society of Anaesthesiologists (ASA) physical status classification I\~III
  • diffusing capacity (DLCO) \<75% at pre op. pulmonary function test

Exclusion Criteria

  • American Society of Anaesthesiologists (ASA) physical status classification IV
  • New York Heart Association (NYHA) class III\~IV
  • Severe obstructive lung disease and/or restrictive lung disease patients
  • patients with end-organ diseases (i.e. heart failure, respiratory failure, hepatic failure, renal failure)
  • arrhythmia
  • pregnant women
  • disease that can influence the DLCO result (anemia, pulmonary vascular disease)

Arms & Interventions

iloprost group

iloprost inhalation group

Intervention: iloprost

control group

normal saline inhalation group

Intervention: normal saline

Outcomes

Primary Outcomes

PaO2(partial pressure of arterial oxygen) ratio

Time Frame: 40 minutes after iloprost inhalation

incidence of intrapulmonary shunt

Time Frame: 40 minutes after iloprost inhalation

Study Sites (1)

Loading locations...

Similar Trials